Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2017; 63(2): 80-85


V. Hayevska, V. Hayevskyy, O. Kovalyshyn

    Lviv National Medical University named by Danylo Halytskyy


We evaluated spontaneous phagocytic activity of monocytes and the reserved capacity of neutrophils in patients with systemic sclerosis with pulmonary injury of various kinds: pneumofibrosis and pulmonary hypertension. We found that among patients with systemic sclerosis, lung injury was observed in 71.6%, including 52.8% with pneumofibrosis, 11.4% with pulmonary hypertension and 35.8% with a combination of these pathologies. Analysis of phagocytic system in the groups of patients showed: an increased spontaneous neutrophil phagocytic activity in patients with systemic sclerosis and lung damage, which is 33.3% higher as compared to patients with systemic sclerosis without lung damage. These changes are more pronounced in patients with a combination of pneumofibrosis and pulmonary hypertension (P <0.001). At the same time, reducing the backup of phagocytic ability of monocytes were found in patients with systemic sclerosis and pneumofibrosis, which is 37.8% lower as compared with patients with combination of pneumofibrosis and pulmonary hypertension, and 21.1% lower in patients with pulmonary hypertension. Thus, studies of phagocytosis of neutrophils and monocytes gave us the opportunity to identify groups of patients with systemic sclerosis without damaging the lungs to group of the patients with initial changes in lung tissue, later verified by computer tomography (19.1%).

Keywords: systemic sclerosis; lung damage; phagocytosis.


  1. Poormoghim H. Systemic sclerosis: demographic, clinical and serological features in patients. Rheumatol Int. 2013; 33: 1943–50. CrossRef PubMed
  3. Tamby M, Chanseaud Y, Guillevin L, et al. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev. 2003; 2: 152–157. CrossRef  
  4. Gutsche M, Rosen D, Swigris J. Connective tissue diseaseassociated interstitial lung disease: a review. Curr Respir Care Rep. 2013; 1(21): 224–232.
  6. Dooley A. Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants. Cardiol Res Pract. 2012; 33: 1155–62. CrossRef  
  7. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis. 2007; 66(38): 940–944. CrossRef PubMed PubMedCentral
  9. Dovzhansky S. Clinical and immunological parallels with limited systemic scleroderma. Cutaneous and Ven Bol. 2009; 25: 26–29 [Ukrainian].
  11. Dumit V, Küttner V, Käppler J, Piera-Velazquez S, et al Altered MCM protein levels and autophagic flux in aged and systemic sclerosis dermal fibroblasts. J Invest Dermatol. 2014; 18, 134:2321–30. CrossRef PubMed PubMedCentral
  13. Kuwana M. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol. 2012; 23: 258–63.
  15. McNearney T, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum. 2007; 57(45): 318–26. CrossRef PubMed
  17. De Lauretis A, Veeraraghavan S, Renzoni E. Connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011; 8: 53–82. CrossRef PubMed
  19. Castello-Cros R, Whitaker-Menezes D, Molchansky A. Scleroderma-like properties of skin from caveolin-1- deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis. Cell Cycle. 2011; 32 (10): 2140–50. CrossRef PubMed PubMedCentral
  21. Fischer A, Meehan RT, Feghali-Bostwick CA, et al. Unique characteristics of systemic sclerosis sine sclerodermaassociated interstitial lung disease. Chest J. 2006; 30 (130): 976–81. CrossRef PubMed
  23. Czirjak L. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2013; 71: 1355-60.
  25. Bukhari SN, Tajuddin Y, Benedict VJ Synthesis and evaluation of chalcone derivatives as inhibitors of neutrophils' chemotaxis, phagocytosis and production of reactive oxygen species. Chem Biol Drug Des. 2014; 83(2):198-206. CrossRef PubMed
  27. Solomon J, Amy L, Aryeh F. Scleroderma lung disease. Eur Respir Rev. 2013; 1: 6–19. CrossRef PubMed PubMedCentral
  29. Sanchez V, Hansmannb G, Klepetkoc A. ESC/ERS pulmonary injury guidelines and connective tissue disease. Allergol Int. 2011; 60(4): 419–24.
  31. Rockall AG, Rickards PJ. Imaging of the pulmonary manifestations of systemic disease. Postgrad Med J. 2001; 34: 621–38. CrossRef PubMedCentral
  33. Highland KB, Garin MC, Brown KK. The spectrum of scleroderma lung disease. Semin Respir Crit Care Med. 2007; 48: 418–29. CrossRef PubMed
  35. Wite M. Pulmonary blood volume indexed to lung volume is reduced in newly diagnosed systemic sclerosis compared to normals - a prospective clinical cardiovascular magnetic resonance study addressing pulmonary vascular changes. J Cardiovasc Magn Reson. 2013; 25: 86–92.
  37. Wigley F. Vascular disease in scleroderma. Clini Rev Allergy and Immunol. 2009; 36(25): 150–74. CrossRef PubMed

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.